Bicara Therapeutics (BCAX) Income towards Parent Company (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Income towards Parent Company of -$56.2 million for Q1 2026, down 52.56% year-over-year from -$118.5 million in Q1 2025, and down 50.35% quarter-over-quarter from -$37.4 million in Q4 2025.
Bicara Therapeutics (BCAX) Income towards Parent Company (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$56.2 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 52.56% year-over-year to -$56.2 million; the TTM figure through Mar 2026 stood at -$157.3 million (down 70.38% YoY), while the FY2025 annual figure was -$138.0 million, down 102.88% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$56.2 million, down from -$37.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$12.4 million in Q4 2023, with the low at -$56.2 million in Q1 2026.
- The 4-year median for Income towards Parent Company is -$22.8 million (2023), against an average of -$27.0 million.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company grew 23.48% in 2024, then plunged 194.58% in 2025.
- Bicara Therapeutics' Income towards Parent Company stood at -$12.4 million in 2023, then sank by 68.46% to -$21.0 million in 2024, then plunged by 78.39% to -$37.4 million in 2025, then slumped by 50.35% to -$56.2 million in 2026.
- Business Quant data shows BCAX's Income towards Parent Company at -$56.2 million in Q1 2026, -$37.4 million in Q4 2025, and -$36.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.44 Mn |
| Mar 31, 2026 | -56.21 Mn |
| Dec 31, 2025 | -37.39 Mn |
| Sep 30, 2025 | -36.33 Mn |
| Jun 30, 2025 | -27.39 Mn |
| Mar 31, 2025 | -36.85 Mn |
| Dec 31, 2024 | -20.96 Mn |
| Sep 30, 2024 | -17.48 Mn |
| Jun 30, 2024 | -17.05 Mn |
| Mar 31, 2024 | -12.51 Mn |
| Dec 31, 2023 | -12.44 Mn |
| Sep 30, 2023 | -22.85 Mn |